Daily Stock Analysis, AGLE, Aeglea Bio Therapeutics Inc, priceseries

Aeglea Bio Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
4.44
Close
4.50
High
4.60
Low
4.26
Previous Close
4.43
Daily Price Gain
0.07
YTD High
8.14
YTD High Date
Mar 20, 2017
YTD Low
3.66
YTD Low Date
Jan 31, 2017
YTD Price Change
-0.07
YTD Gain
-1.53%
52 Week High
10.34
52 Week High Date
Nov 21, 2016
52 Week Low
3.66
52 Week Low Date
Jan 31, 2017
52 Week Price Change
-2.74
52 Week Gain
-37.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 15. 2016
4.69
Aug 19. 2016
5.17
4 Trading Days
10.14%
Link
LONG
Sep 1. 2016
5.79
Sep 19. 2016
7.13
11 Trading Days
23.30%
Link
LONG
Feb 9. 2017
4.59
Mar 7. 2017
5.71
17 Trading Days
24.22%
Link
Company Information
Stock Symbol
AGLE
Exchange
NasdaqGM
Company URL
http://www.aegleabio.com
Company Phone
(512) 942-2935
CEO
David G. Lowe
Headquarters
Texas
Business Address
901 S. MOPAC EXPRESSWAY, STE. 250, BARTON OAKS PLAZA ONE, AUSTIN, TX 78746
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001636282
About

Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer.

Description

Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.